KCTD9 Antibody - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-57662
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Format
BSA Free
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptides corresponding to KCTD9 (potassium channel tetramerisation domain containing 9) The peptide sequence was selected from the middle region of KCTD9.
Peptide sequence AHANLCCANLERADLSGSVLDCANLQGVKMLCSNAEGASLKLCNFEDPSG. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for KCTD9 Antibody - BSA Free
Western Blot: KCTD9 Antibody [NBP1-57662]
Western Blot: KCTD9 Antibody [NBP1-57662] - COLO205 cells lysate, concentration 0.2-1 ug/ml.Applications for KCTD9 Antibody - BSA Free
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Format
BSA Free
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: KCTD9
Alternate Names
BTB/POZ domain-containing protein KCTD9, FLJ20038, potassium channel tetramerisation domain containing 9
Gene Symbol
KCTD9
UniProt
Additional KCTD9 Products
Product Documents for KCTD9 Antibody - BSA Free
Product Specific Notices for KCTD9 Antibody - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...